切换至 "中华医学电子期刊资源库"
高级检索
中华眼科医学杂志(电子版)

中华眼科医学杂志(电子版) ›› 2017, Vol. 07 ›› Issue (06) : 250 -256. doi: 10.3877/cma.j.issn.2095-2007.2017.06.003

所属专题： 文献；

论著

自制吡非尼酮滴眼液局部应用于角膜的安全性研究
吴共发1, 邱丽浈2, 曾宇婷3, 黄绮亭3, 刘钰君3, 李海刚1,†()   
  1. 1. 511300　广州市增城区人民医院（中山大学孙逸仙纪念医院增城院区）病理科；510120　广州市，中山大学孙逸仙纪念医院病理科
    2. 511300　广州市增城区人民医院（中山大学孙逸仙纪念医院增城院区）内三科
    3. 510120　广州市，中山大学孙逸仙纪念医院病理科
  • 收稿日期:2017-11-08 出版日期:2017-12-28
  • 通信作者: 李海刚
  • 基金资助:
    广东省医学科研基金(A2016422); 广州市增城区人民医院优秀医学人才培育基金(2017－YX－001)

Research on the ocular safety of the developed pirfenidone eye drops application

Gongfa Wu1, Lizhen Qiu2, Yuting Zeng3, Qiting Huang3, Yujun Liu3, Haigang Li1,†()   

  1. 1. Department of Pathology, Zengcheng District People′s Hospital of Guangzhou, Guangzhou 511300;Department of Pathology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou 510120, China
    2. Third Department of Internal Medicine, Zengcheng District People′s Hospital of Guangzhou, Guangzhou 511300, China
    3. Department of Pathology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou 510120, China
  • Received:2017-11-08 Published:2017-12-28
  • Corresponding author: Haigang Li
  • About author:
    Corresponding author: Li Haigang, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

吴共发, 邱丽浈, 曾宇婷, 黄绮亭, 刘钰君, 李海刚. 自制吡非尼酮滴眼液局部应用于角膜的安全性研究[J]. 中华眼科医学杂志(电子版), 2017, 07(06): 250-256.

Gongfa Wu, Lizhen Qiu, Yuting Zeng, Qiting Huang, Yujun Liu, Haigang Li. Research on the ocular safety of the developed pirfenidone eye drops application[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2017, 07(06): 250-256.

目的

探讨自制吡非尼酮(PFD)滴眼液局部应用于角膜的安全性。

方法

选择18只远交群大鼠，采用数字表法随机将大鼠分为对照组、实验1组及实验2组，每组6只。对照组大鼠以磷酸盐缓冲液(PBS)滴眼，实验1组和实验2组大鼠分别以3 mg/ml和30 mg/ml的PFD滴眼液滴眼，全部大鼠每天滴眼6次，连续14 d。每次滴眼液滴眼后，观察并记录大鼠接触滴眼液后所产生的刺激反应情况，包括有无抓挠眼部、频繁眨眼或甩头等行为。裂隙灯显微镜下观察大鼠的结膜、角膜及虹膜组织等眼表情况，应用荧光素钠染色检查排查角膜是否存在损伤情况，参照Draize的兔眼刺激性实验评分标准对大鼠进行评分，比较第14 d时三组大鼠眼表的损伤情况。三组大鼠结束滴眼后，将10%水合氯醛按照3.5 ml/kg用量配置，对大鼠进行腹腔注射。充分麻醉后，在眼科手术显微镜下取大鼠的眼结膜和角膜，置于4%的中性缓冲甲醛固定液中固定4 h，行病理常规苏木精－伊红染色，生物显微镜下进行观察并进行显微照相。刺激性行为的描述采用例数和百分比，组间比较采用χ2检验。大鼠刺激行为持续时间和Draize眼刺激性实验评分数据采用均数±标准差(±s)进行描述，组间比较采用单因素方差分析。

结果

对照组、实验1组及实验2组的大鼠在滴眼后，均立即出现抓挠眼部的行为，约持续20～30 min后消失。统计结果显示，对照组、实验1组和实验2组的大鼠接受滴眼液处理后均无明显刺激性行为学改变，差异无统计学意义(χ2＝－1.098，P>0.05)。对照组、实验1组及实验2组大鼠的刺激性行为持续时间分别为(23.50±1.87)min、(24.83±3.06)min及(25.67±2.81)min，差异无统计学意义(F＝1.04，P>0.05)。对照组、实验1组及实验2组的结膜、角膜及虹膜Draize评分分别为0.33±0.52、0.50±0.55及0.83±0.75。采用单向方差分析的统计结果显示，对照组、实验1组及实验2组的结膜、角膜和虹膜Draize评分差异均无统计学意义(F＝1.03，P>0.05)。苏木精－伊红染色的病理切片显示，对照组、实验1组及实验2组大鼠的角膜和结膜上皮完整，角膜基质排列规则有序，未见病理性改变。

结论

PFD滴眼液眼局部应用于角膜的安全性良好，具有良好的应用前景。

关键词: 吡非尼酮滴眼液, 角膜, 安全性
Objective

To study the ocular safety of the developed pirfenidone(PFD) eye drops application.

Methods

18 isolated rats were selected. The rats were divided into the control group, the experiment 1 groups and the experiment 2 groups according to the random number table method, with 6 rats in each group. The rats in the control group were treated with phosphate buffer (PBS). The 1 groups and the experimental 2 groups were eyedrops of 3 mg/ml and 30 mg/ml PFD respectively. All eyes were dropped 6 times a day for 14 days.The irritant behavior of the rats was observed and recorded after each eye drops. It includes the eye, frequent blinking or head scratching. The conjunctival, corneal and iris tissues were observed under slit lamp microscope. Fluorescein sodium staining was used to check whether there was any damage to the cornea. According to Draize′s rabbit eye irritation test score, rats were scored. The damage of the ocular surface of the three groups of rats was compared for fourteenth days.At the end of the three group of rats, fourteenth days after the experiment, 10% chloral chloral aldehyde was assigned to 3.5 ml/kg, and the rats were injected intraperitoneally. After anesthesia, the conjunctiva and cornea of rats were taken under the microscope of eye surgery. They were placed in 4% neutral buffer formaldehyde fixative for 4 hours. Pathological hematoxylin eosin staining was performed, and observed under microscope.The number and percentage of the stimuli were described by the χ2 test.The duration of stimulation behavior and the score of Draize eye irritation test were described with mean standard deviation (±s), and the single factor analysis of variance was used.

Results

The control group, experimental group 1 and experimental group 2 rats in the use of eye drops, eye immediately scratching behavior, disappeared last about 20~30 minutes. The statistical results showed that the rats in the control group, the experiment group 1 and the experimental group 2 were treated with eye drops, there was no significant difference in stimulus behavior, and there was no statistical difference (χ2=-1.098, P>0.05). The duration of stimulation in the control group, the group1 and the group 2 were (23.50±1.87)min, (24.83±3.06)min and (25.67±2.81)min. The difference was not statistically significant (F=1.04, P>0.05). The control group, experimental group 1 and experimental group 2 of the conjunctiva, cornea and iris Draize score were 0.33±0.52, 0.50±0.55 and 0.83±0.75, way analysis of variance results showed that the control group, experimental group 1 and experimental group 2 of the conjunctiva, cornea and iris Draize score difference was not statistically significant (F=1.03, P>0.05). Hematoxylin-eosin staining demonstrated that the morphology and structure of ocular tissues in the experimental group one, the experimental group two and control group were normal, and there were no significant pathological changes.

Conclusion

The local application of PFD eye drops and the safety of cornea are good and have good prospects for application.

Key words: Pirfenidone eye drops, Cornea, Safety
表1 Draize眼刺激性实验的评分标准[7]
组织 损伤情况 分值
角膜 ? A.混浊(以最致密部位计算) ?
散在或弥漫性混浊，虹膜清晰可见 1
半透明区易分辨，虹膜清晰可见 2
出现乳白色区域，虹膜细节不清，瞳孔大小勉强可见 3
角膜不透明，虹膜无法辨认 4
? B.角膜损害面积 ?
? ≤25% 1
? >25%，≤50% 2
? >50%，≤75% 3
? >75% 4
? 积分＝A×B×5 ?
虹膜 ? A.数值 ?
皱褶加深、充血及肿胀，角膜周围轻度充血，瞳孔对光有反应 1
? 出血、肉眼可见坏死，对光无反应 2
? 积分＝A×5 ?
结膜 ? A.睑结膜充血 ?
充血重于正常血管 1
呈深红色弥漫性充血，血管不易分辨 2
呈紫红色充血 3
? B.水肿 ?
任何重于正常的肿胀 1
明显水肿，伴部分眼睑外翻 2
水肿至眼睑闭合近一半 3
水肿至眼睑闭合超过一半 4
? C.分泌物 ?
分泌物异于正常 1
分泌物仅使眼睑和睫毛潮湿 2
分泌物使眼睑和眼周大面积潮湿 3
? 积分＝(A＋B＋C)×2 ?
表2 对照组、实验1组及实验2组刺激性行为及刺激症状持续时间情况的比较(±s)
分组 刺激性行为 持续时间(min)
－[%(例数/总例数)] ＋[%(例数/总例数)] ＋＋[%(例数/总例数)]
对照组 0.00(0/6) 83.33(5/6) 16.67(1/6) 23.50±1.87
实验1组 0.00(0/6) 50.00(3/6) 50.00(3/6) 24.83±3.06
实验2组 0.00(0/6) 50.00(3/6) 50.00(3/6) 25.67±2.81
统计量 χ2＝1.77 F＝1.04
P值 >0.05 >0.05
图1 三组大鼠的眼角膜组织形态(HE×200)　A图示对照组，B图示实验1组，C图示实验2组。三组大鼠角膜被覆的复层扁平上皮均完整，基质纤维平行排列成层，无血管，未见炎症细胞浸润，角膜内皮完整连续
图2 三组大鼠的眼结膜组织形态(HE×100)　A图示对照组，B图示实验1组，C图示实验2组。三组大鼠的眼结膜上皮均完整，结膜皮下疏松结缔组织无水肿及淤血，未见炎症细胞浸润
[1]
黄晓波,邹海东,王宁, 等. 上海市北新泾街道60岁及以上人群盲和视力损伤的现况调查[J]. 中华眼科杂志, 2009, 45(9): 786-792.
[2]
李运,毕宏生,王利华, 等. 山东省农村50岁及以上人群盲和中、重度视力损伤病因分析[J]. 中华眼科杂志, 2013, 49(2): 144-150.
[3]
尉洋,向云,生侠, 等. 海口市郊≥50岁人群的视力损伤及患盲病率调查[J]. 国际眼科杂志, 2012, 12(9): 1806-1808.
[4]
Whitcher JP,Srinivasan M,Upadhyay MP. Corneal blindness: a global perspective[J]. Bull World Health Organ, 2001, 79(3): 214-221.
[5]
George PM,Wells AU. Pirfenidone for the treatment of idiopathic pulmonary fibrosis[J]. Expert Rev Clin Pharmacol, 2017, 10(5): 483-491.
[6]
国家科学技术委员会. 实验动物管理条例[Z]. 2013－7－18.
[7]
Draize JH,Woodard G,Calvery HO. Methods for the Study of Irritation and Toxicity of Substances Applied Topically to the Skin and Mucous Membranes[J]. J Pharmacol Expe Ther, 1944, 6(3): 377-390.
[8]
Meek KM,Knupp C. Corneal structure and transparency[J]. Prog Retin Eye Res, 2015, 49(2): 1-16.
[9]
黄一飞,王大江,王丽强, 等. 人工角膜在治疗严重化学烧伤眼中的研究[J]. 中华眼科杂志, 2007, 43(4): 297-302.
[10]
Nili－Ahmadabadi M,Oskouee SJ,Hashemian MN, et al. Epidemiology of ocular trauma in Tehran, Iran: A retrospective survey of 959 cases[J]. Int J Ophthalmol, 2008, 8(10): 1975-1979.
[11]
MGG Jr,Xie A,Owsley C. Rate of eye injury in the United States[J]. Arch Ophthalmol, 2005, 123(7): 970-976.
[12]
Hilber D,Mitchener TA,Stout J, et al. Eye injury surveillance in the U. S. Department of Defense, 1996－2005[J]. Am J Prev Med, 2010, 38(Suppl. 1): 78-85.
[13]
MGG Jr,Owsley C. Incidence of emergency department－treated eye injury in the United States[J]. Arch Ophthalmol, 2005, 123(5): 662-666.
[14]
West－Mays JA,Dwivedi DJ. The keratocyte: corneal stromal cell with variable repair phenotypes[J]. Int J Biochem Cell Biol, 2006, 38(10): 1625-1631.
[15]
樊廷俊,白苏冉. 角膜基质创伤愈合的研究进展[J]. 山东大学学报(理学版), 2016, 51(3): 1-10.
[16]
Hassell JR,Birk DE. The molecular basis of corneal transparency[J]. Exp Eye Res, 2010, 91(3): 326-333.
[17]
许杨,肖骏,杨晓梅, 等. 准分子激光治疗12例角膜瘢痕的效果观察[J]. 浙江预防医学, 2000, 12(6): 50-51.
[18]
高桂平,邵毅,周琼, 等. 260例角膜移植常见病因分析[J]. 江西医药, 2007, 42(1): 50-51.
[19]
李小磊,宋秀君,卢建民, 等. 姜黄素对角膜基质细胞纤维化的抑制作用[J]. 中华实验眼科杂志, 2011, 29(5): 402-406.
[20]
牟章兵,杜之渝,晏丕松, 等. 汉防己甲素等5种抗纤维化药物对离体兔角膜基质细胞的抑制作用[J]. 眼科新进展, 2006, 26(8): 592-596.
[21]
李红,张作明,杨新光, 等. 退翳眼液对兔角膜瘢痕厚度及面积影响的实验研究[J]. 中国临床康复, 2004, 8(11): 2091-2093.
[22]
Ke Y,Wu Y,Cui X, et al. Polysaccharide hydrogel combined with mesenchymal stem cells promotes the healing of corneal alkali burn in rats[J]. PLoS One, 2015, 10(3): e0119725.
[23]
Giulio F,Fabio B,Chiara G, et al. Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring[J]. Invest Ophthalmol Vis Sci, 2013, 54(3): 1680-1688.
[24]
Stramer BM,Zieske JD,Jung JC, et al. Molecular mechanisms controlling the fibrotic repair phenotype in cornea: implications for surgical outcomes[J]. Invest Ophthalmol Vis Sci, 2003, 44(10): 4237-4246.
[25]
Milani BY,Milani FY,Park DW, et al. Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy[J]. Invest Ophthalmol Vis Sci, 2013, 54(12): 7424-7430.
[26]
唐敏,席头华,唐罗生, 等. 人羊膜匀浆提取液对兔角膜成纤维细胞增殖和TGF－β1 mRNA表达的影响[J]. 眼科新进展, 2013, 33(11): 1029-1032.
[27]
Owens GM. Strategies to manage costs in idiopathic pulmonary fibrosis[J]. Am J Manag Care, 2017, 23(Suppl. 11): 191-196.
[28]
Tzouvelekis A,Bouros E,Tzilas V, et al. Pirfenidone in Idiopathic Pulmonary Fibrosis "RECAP－itulating Safety into the Real World"[J]. Respiration, 2017, 94(5): 405-407.
[29]
徐建华,肖红波,程玉花, 等. 吡非尼酮对大鼠肾间质纤维化的防治作用研究[J]. 中国现代医学杂志, 2017, 27(19): 1-6.
[30]
肖敏,屈小虎,吕聚坪, 等. 吡非尼酮对四氯化碳诱导的小鼠肝纤维化的影响[J]. 中国应用生理学杂志, 2016, 32(4): 378-382.
[31]
Iyer SN,Wild JS,Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin－induced lung fibrosis in hamsters[J]. Journal of Laboratory & Clinical Medicine, 1995, 125(6): 779-785.
[32]
Tzouvelekis A,Ntolios P,Karampitsakos T, et al. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis a real－world observational study[J]. Pulm Pharmacol Ther, 2017, 46(5): 48-53.
[33]
王红梅,杨佳丹,蒙龙, 等. 吡非尼酮治疗特发性肺纤维化疗效与安全性的系统评价[J]. 中国药房, 2016, 27(3): 345-348.
[34]
付麟紫,吴晓梅. 特发性肺纤维化药物治疗推荐[J]. 中华老年多器官疾病杂志, 2017, 16(3): 234-237.
[35]
李云霞,李琼,加慧, 等. 吡非尼酮治疗特发性肺纤维化的临床研究[J]. 航空航天医学杂志, 2016, 27(11): 1365-1367.
[36]
陈钰清,闫永吉,仇美华, 等. 吡非尼酮治疗肺纤维化的疗效与安全性meta分析[J]. 临床药物治疗杂志, 2016, 14(4): 13-22.
[37]
陈俊杰,吴共发,林俊汕, 等. 吡非尼酮对大鼠角膜基质细胞增殖的影响[J]. 国际眼科杂志, 2015, 15 (2): 201-204.
[38]
Liu H,Drew P,Gaugler AC, et al. Pirfenidone inhibits lung allograft fibrosis through L－arginine－arginase pathway[J]. American Journal of Transplantation, 2015, 5(6): 1256-1263.
[39]
Choi K,Lee K,Ryu SW, et al. Pirfenidone inhibits transforming growth factor－β1－induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE－19[J]. Molecular Vision, 2012, 18(104): 1010-1020.
[40]
Iyer SN,Gurujeyalakshmi G,Giri SN. Effects of Pirfenidone on Procollagen Gene Expression at the Transcriptional Level in Bleomycin Hamster Model of Lung Fibrosis[J]. Journal of Pharmacology & Experimental Therapeutics, 1999, 289(1): 211-218.
[41]
Hewitson TD,Kelynack KJ,Tait MG, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis[J]. Journal of Nephrology, 2001, 14(6): 453-460.
[42]
Gurujeyalakshmi G,Hollinger MA,Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level[J]. American Journal of Physiology, 1999, 276(1): 311-318.
[43]
Oku H,Nakazato H,Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor－alpha, enhances interleukin－10 and protects mice from endotoxic shock[J]. European Journal of Pharmacology, 2002, 446(1): 167-176.
[44]
Nakazato H,Oku H,Yamane S, et al. A novel anti－fibrotic agent pirfenidone suppresses tumor necrosis factor－alpha at the translational level[J]. European Journal of Pharmacology, 2002, 446(1): 177-185.
[45]
Oku H,Shimizu T,Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin－induced murine pulmonary fibrosis[J]. European Journal of Pharmacology, 2008, 590(1): 400-408.
[46]
Grattendick KJ,Nakashima JM,Feng L, et al. Effects of three anti－TNF－alpha drugs: etanercept, infliximab and pirfenidone on release of TNF－alpha in medium and TNF－alpha associated with the cell in vitro[J]. Int Immunopharmacol, 2008, 8(5): 679-687.
[47]
Schaefer CJ,Ruhrmund DW,Pan L, et al. Antifibrotic activities of pirfenidone in animal models[J]. Eur Respir Rev, 2011, 20(120): 85-97.
[48]
杜磊,王昌源,张立华, 等. 吡非尼酮对实验性大鼠肝纤维化的作用[J]. 山东大学学报(医学版), 2009, 47(11): 50-54.
[49]
王琳娜,陈常勇,郭存霞, 等. 吡非尼酮对转化生长因子－β1诱导的大鼠心肌成纤维细胞增殖和胶原蛋白合成的影响[J]. 中国现代医学杂志, 2015, 25(29): 30-34.
[50]
姬巍,蒋恒,杨伟志, 等. 吡非尼酮防治放射性肺纤维化实验研究[J]. 中华放射肿瘤学杂志, 2010, 19(6): 560-563.
[51]
Tian XL,Yao W,Guo ZJ, et al. Low dose pirfenidone suppresses transforming growth factor beta－1 and tissue inhibitor of metalloproteinase－1, and protects rats from lung fibrosis induced by bleomycina[J]. Chin Med Sci J, 2006, 21(3): 145-151.
[52]
Waller JR,Murphy GJ,Bicknell GR, et al. Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats[J]. Eur J Vasc Endovasc Surg, 2002, 23(3): 234-240.
[53]
Lin X,Yu M,Wu K, et al. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon′s fibroblasts in vitro[J]. Invest Ophthalmol Vis Sci, 2009, 50(8): 3763-3770.
[54]
Zhong H,Sun G,Lin X, et al. Evaluation of pirfenidone as a new postoperative anti－scarring agent in experimental glaucoma surgery[J]. Invest Ophthalmol Vis Sci, 2011, 52(6): 3136-3142.
[55]
Yang Y,Ye Y,Lin X, et al. Inhibition of Pirfenidone on TGF－beta2 Induced Proliferation, Migration and Epithlial－Mesenchymal Transition of Human Lens Epithelial Cells Line SRA01/04[J]. Plos One, 2013, 8(2): e56837.
[56]
Kim H,Choi YH,Park SJ, et al. Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid－associated ophthalmopathy by decreasing TIMP－1 and collagen levels[J]. Invest Ophthalmol Vis Sci, 2010, 51(6): 3061-3066.
[57]
Chung SA,Jeon BK,Choi YH, et al. Pirfenidone attenuates the IL－1β－induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid－associated ophthalmopathy[J]. Invest Ophthalmol Vis Sci, 2014, 55(4): 2276-2283.
[58]
李亨辉,李云燕,邵毅, 等. 吡非尼酮滴眼液在兔眼青光眼手术中应用研究[J]. 中国实用眼科杂志, 2015, 33(10): 1179-1184.
[59]
Wilson SE. Corneal myofibroblast biology and pathobiology: Generation, persistence, and transparency[J]. Experimental Eye Research, 2012, 99(1): 78-88.
[60]
邵毅,余瑶,裴重刚, 等. 吡非尼酮滴眼液在兔眼小梁切除术后抗瘢痕作用研究[J]. 中国现代医学杂志, 2015, 25(2): 13-17.
[61]
Nakayama S,Mukae H,Sakamoto N, et al. Pirfenidone inhibits the expression of HSP47 in TGF－beta1－stimulated human lung fibroblasts.[J]. Life Sciences, 2008, 82(3): 210-217.
[62]
Suga H,Teraoka S,Ota K, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats[J]. Experimental & Toxicologic Pathology, 1995, 47(4): 287-291.
[63]
Garcã AL,Hernã NL,Sandoval A, et al. Pirfenidone effectively reverses experimental liver fibrosis[J]. Journal of Hepatology, 2002, 37(6): 797-805.
[64]
Ramachandrarao SP,Zhu Y,Ravasi T, et al. Pirfenidone Is Renoprotective in Diabetic Kidney Disease[J]. Journal of the American Society of Nephrology Jasn, 2009, 20(8): 1249-1256.
[65]
Hijikawa T,Kwon AH. Effects of pirfenidone on endotoxin－induced liver injury after partial hepatectomy in rats[J]. Transplant Proc, 2004, 36(7): 1975-1976.
[66]
Gurujeyalakshmi G,Hollinger MA,Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level[J]. American Journal of Physiology, 1999, 276(2 Pt 1): 311-318.
[67]
Nagai S,Hamada K,Shigematsu M, et al. Open－label compassionate use one year－treatment with pirfenidone to patients with chronic pulmonary fibrosis[J]. Internal Medicine, 2002, 41(12): 1118-1123.
[1] 熊风, 林辉煌, 陈晓波. 铥激光在泌尿外科中的临床应用及研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 533-536.
[2] 彭永辉, 张文杰, 李炳根, 聂向阳, 吴凯, 杨六成. 单孔双针疝囊高位结扎术在儿童巨大腹股沟疝的临床应用[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(05): 566-569.
[3] 刘骏, 朱霁, 殷骏. 右美托咪定对腹股沟疝手术麻醉效果及安全性的影响[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(05): 570-573.
[4] 王红敏, 谢云波, 王彦虎, 王福生. 间充质干细胞治疗新冠病毒感染的临床研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 247-256.
[5] 王峰杰, 王礼光, 廖珊, 刘颖, 符荣党, 陈焕伟. 腹腔镜右半肝切除术治疗肝癌的安全性与疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 517-522.
[6] 娜荷雅, 朱丹. 红光疗法在儿童近视眼防控中的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(04): 252-256.
[7] 赵欣, 赵晴, 张华. 角膜地形图引导个性化切削屈光术矫正近视眼和散光的早期临床疗效[J]. 中华眼科医学杂志(电子版), 2023, 13(04): 210-214.
[8] 唐凯, 刘正峰, 宋佳蔚, 卢秀珍. 角膜巩膜干凹斑的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(04): 231-235.
[9] 崔梦凡, 贺瑞, 李晓娜, 陈维毅, 宋耀文. 角膜生物力学评估参数的应用进展[J]. 中华眼科医学杂志(电子版), 2023, 13(04): 236-240.
[10] 江卓婷, 高妍, 李春晖. 相干光断层扫描在角膜屈光手术术前筛查中应用的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(04): 247-251.
[11] 梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
[12] 陈婷婷, 江学良, 余佳丽, 柯剑林. 干细胞治疗炎症性肠病的安全性[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 193-198.
[13] 朴成林, 蓝炘, 司振铎, 冯健, 安峰铎, 李强, 谈明坤, 赵娜, 冷建军. 局部晚期右半结肠癌行结肠癌根治联合胰十二指肠切除术疗效分析：附5例报告[J]. 中华临床医师杂志(电子版), 2023, 17(06): 666-670.
[14] 曹文玺, 陈箫, 竺来法, 周永平. 尼妥珠单抗联合白蛋白结合型紫杉醇治疗胰腺癌的有效性及安全性分析[J]. 中华临床医师杂志(电子版), 2023, 17(04): 409-413.
[15] 梁君, 褚晨宇, 孙凤艳, 袁仪浪, 周曦, 王卫东. 胸壁完全植入式静脉输液港术中隧道针逆向穿刺的可行性和安全性[J]. 中华介入放射学电子杂志, 2023, 11(04): 310-313.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号